Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERAVANCE BIOPHARMA, INC.

(TBPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Theravance Biopharma : JPMorgan Downgrades Theravance Biopharma to Underweight From Overweight, Adjusts Price Target to $7 From $17

09/15/2021 | 12:46pm EDT


ę MT Newswires 2021
All news about THERAVANCE BIOPHARMA, INC.
10/05THERAVANCE BIOPHARMA : Change in Directors or Principal Officers, Financial Statements and..
AQ
09/23Certain Restricted Stock Units of Theravance Biopharma, Inc. are subject to a Lock-Up A..
CI
09/23Certain Ordinary Shares of Theravance Biopharma, Inc. are subject to a Lock-Up Agreemen..
CI
09/23Certain Options of Theravance Biopharma, Inc. are subject to a Lock-Up Agreement Ending..
CI
09/16THERAVANCE BIOPHARMA : Needham Downgrades Theravance Biopharma to Hold From Buy
MT
09/16THERAVANCE BIOPHARMA : Baird Adjusts Theravance Biopharma PT to $7 From $10, Maintains Neu..
MT
09/16THERAVANCE BIOPHARMA : Morgan Stanley Adjusts Theravance Biopharma's Price Target to $10 f..
MT
09/16WALL STREET STOCK EXCHANGE : US economy shows resilience, while China falters
09/16THERAVANCE BIOPHARMA : SVB Leerink Cuts Price Target on Theravance Biopharma to $10 From $..
MT
09/16THERAVANCE BIOPHARMA : HC Wainwright Slashes Price Target on Theravance Biopharma to $8 Fr..
MT
More news
Analyst Recommendations on THERAVANCE BIOPHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 58,2 M - -
Net income 2021 -191 M - -
Net Debt 2021 446 M - -
P/E ratio 2021 -2,85x
Yield 2021 -
Capitalization 587 M 587 M -
EV / Sales 2021 17,7x
EV / Sales 2022 10,3x
Nbr of Employees 359
Free-Float 83,3%
Chart THERAVANCE BIOPHARMA, INC.
Duration : Period :
Theravance Biopharma, Inc. Technical Analysis Chart | TBPH | KYG8807B1068 | MarketScreener
Technical analysis trends THERAVANCE BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 7,99 $
Average target price 9,38 $
Spread / Average Target 17,3%
EPS Revisions
Managers and Directors
Rick E. Winningham Chairman & Chief Executive Officer
Andrew Asa Hindman Chief Financial Officer & Senior Vice President
Philip D. Worboys Senior VP-Research & Translational Science
Vijay Sabesan Senior Vice President-Technical Operations
Burton Gordon Malkiel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
THERAVANCE BIOPHARMA, INC.-55.04%587
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657